Skip to content

Yastimadhu ghrita in the management of Melasma/ Mukha Vyanga

A Single Blind Randomised Controlled Clinical Study to evaluate the Varnya and Medhya effect of Yastimadhu ghrita over Manjishta ghrita internally and externally in Mukha Vyanga with special reference to Melasma - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068670
Enrollment
40
Registered
2024-06-11
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L814- Other melanin hyperpigmentation

Interventions

None listed

Sponsors

DrSapna Xavier Lopes
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Classical signs and symptoms of Vyanga like Shyava(brown coloured patches), tanuka(thin,non elevated), niruja(painless) mandalas on mukha, with or without kandu or daha or chimchimata associated with or without manasika hetus. Subjects willing to participate and comply with all study procedures for prescribed trial period. Subjects willing to give a written consent. Age group between 18-55 yrs of either sex. Subject not using any topical treatment for melasma for 2 weeks prior to enrolment to the study.

Exclusion criteria

Exclusion criteria: Any medical conditions, laboratory findings or physical examination findings like vital signs, outside of specific range. If subject is on any concomitant medications like oral contraceptives, thyroid medications and hormone replacement therapies. Known allergic reaction to component of study product. Treatment with other investigatory drug or other intervention within a specific time frame. H/O drug or alcohol abuse. Pregnant and lactating women. Subject who have taken topical or oral steroids within 1 month prior to enrolment. Subject who have taken topical tretinoin within 3 months or topical hydroquinone within 6 months prior to enrolment. Subject under treatment of another dermatological condition. Post Inflammatory Hyperpigmentation(PIH).

Design outcomes

Primary

MeasureTime frame
Changes in signs and symptoms of Melasma such as reduction in the size and colour of the lesion and other symptoms like roughness, itching, tingling if present, observing the safety or no side effects of the intervention undertaken. Improvement in the Melasma Quality Of Life Scale.Timepoint: 90 days

Secondary

MeasureTime frame
Gaining Twak sara purusha lakshana(Good skin health) like unctousness, smoothness, softness, clean, delcate & lustre. Improvement in sleep & appetite of patient.Timepoint: 120 days

Countries

India

Contacts

Public ContactDr Sapna Xavier Lope

Shri DGM Ayurvedic Medical College and Hospital Post Graduate and PhD studies center Gadag

yasmeenphaniband@gmail.com9845515865

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026